Skip to main content

Table 3 Active clinical trials combining radiation with TGF-β blockade or GM-CSF

From: Current clinical trials testing the combination of immunotherapy with radiotherapy

NCT Number Phases Title Condition Intervention RT Details Enrollment Sponsor/Collaborators
Anti-TGF- β
NCT02538471 Phase 2 LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer Metastatic Breast Cancer LY2157299 RT, 7.5 Gy × 3 fx 28 Weill Medical College of Cornell University|University of California, Los Angeles
NCT02581787 Phase 1|Phase 2 SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Stage IA-B NSCLC Fresolimumab SBRT, 4 fx 60 Maximilian Diehn|National Cancer Institute (NCI)|Stanford University
NCT02623595 Phase 2 A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy Non-small cell lung cancer GM-CSF SBRT, 10 Gy × 5 fx 60 Wuhan University|Tongji Hospital|Hubei Cancer Hospital
NCT02663440 Phase 2 Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme Glioblastoma GM-CSF, Temozolomide Hypofx IMRT 41 Zhejiang Cancer Hospital
NCT02677155 Phase 2 Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma Follicular Lymphoma GM-CSF, Pembrolizumab, Rituximab, autologous dendritic cells 8 Gy × 1 20 Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme Corp.
NCT02648282 Phase 2 Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer Pancreatic Cancer GVAX, Cyclophosphamide, Pembrolizumab SBRT, 6.6 Gy × 5 fx 54 Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp.
  1. Abbreviations: GM-CSF granulocyte macrophage colony stimulating factor, Hypofx hypofractionated, IMRT intensity modulated radiation therapy, NSCLC non-small cell lung cancer, SBRT stereotactic body radiation therapy